anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxymorphone, noroxymorphone, and their glucuronides. The major circulating metabolite is noroxycodone with an AUC ratio of 0.6 relative to that of oxycodone. Noroxycodone is reported to be a considerably weaker analgesic than oxycodone. Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations. The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations. The analgesic activity profile of other metabolites is not known. 

The formation of oxymorphone and noroxycodone, is mediated by cytochrome P450 2D6 and cytochrome P450 3A4, respectively. In addition, noroxymorphone formation is mediated by both cytochrome P450 2D6 and cytochrome P450 3A4. Therefore, the formation of these metabolites can, in theory, be affected by other drugs (see Drug-Drug Interactions).
Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.

Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with an altitude change of 3000 meters. At the chamber site, the subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow-up phone call to check on subjects will then be done on day 5 before closing the study.
There is no clinical evidence on which are the best treatment options for Periprosthetic and Peri-implant fractures of the upper and lower limb. This is a multi-center collaborative study seeking to obtain a big number of patients. Data collection includes previous health status and quality of life, which is the clinical management and treatment, as well as the outcome after one month, six months and one year. The investigators will be able to define risk factors and clinical attitudes, which influence on the patient outcome. And therefore, be able to establish treatment protocols and give management recommendations based on the observed clinical evidence to improve healing indexes, morbidity and mortality, function, grade of autonomy and quality of live.

Main questions to be answered are: 1. which is the epidemiology of Periprosthetic and Peri-implant fractures and how are they treated in Spain, 2. Identify risk factors for complications and worse outcomes, 3. which is the morbidity and mortality, 4. influence of the fracture type and implants already placed on management and outcome, 5. influence of the treatment on patients' grade of independency, and 6. identified which are the risk factors for treatment failure.
Enteric duplication has cystic and tubular varieties. A male infant presented with a large cystic, well-demarcated mass in the right flank. On exploratory laparotomy, multiple cystic and tubular lesions were present adjacent to the mesenteric border of the small bowel along with malrotation of the small bowel. The tubule-cystic structure was excised along with the involved normal bowel segment and Ladd's procedure was performed. Histopathological evaluation revealed an intestinal duplication cyst. The occurrence of midgut malrotation and volvulus along with duplication is uncommon. The cyst's substantial size could have been an aetiological factor for malrotation and volvulus. The child's small bowel had adapted remarkably with time. This case highlights a new variant of duplication cysts.
Patients undergo surgical resection with standard intraoperative guidance using contrast-enhanced MRI. Patients also undergo post operative standard of care radiation therapy over 30 fractions and receive standard of care temozolomide PO for 6 weeks. Additionally, patients undergo MRI during follow up.
A method for producing a chewing gum, as well as the chewing gum so produced, incorporates a physiological cooling agent, such as acyclic carboxamide, or combinations of physiological cooling agents. In another embodiment a combination of physiological cooling agents is made in a modified release structure. The modified release/cooling agents combination is preferably obtained by physically modifying the properties of the combination of cooling agents by coating and drying. When incorporated into gum, these particles are adapted to enhance the shelf stability of the flavor and/or produce a modified release when the gum is chewed. In another embodiment, the physiological cooling agent is present with menthol and menthone. In another embodiment, coated chewing gum has a coating that comprises a physiological cooling agent. The preferred inventive chewing gum provides a high flavor impact in which the harsh notes normally associated with such a high flavor impact have been reduced or eliminated. In addition, the preferred inventive gum provides a clean, high-quality, cooling chewing gum coating with xylitol or other polyols where xylitol has been reduced in concentration or eliminated.
1. New alginate macromolecules with anti-arrhythmia activity, characterised in that they consists of: 0.71-0.78 parts by mass of sodium alginate binder, 0.24-0.26 parts by mass of the hydrophilising agent in the form of polioxyethylene-20-sorbitan monostearate (Tween 60). 3.8-4.2 parts by mass of quinidine base adsorbed into potato starch. The mixture contains 2.9-3.1 parts by mass of starch and 0.935-1.075 parts by mass of quinidine base. 2. The method of obtaining new alginate macromolecules with anti-arrhythmia activity, characterised in that 0.71-0.78 parts by mass of sodium alginate is converted into pap in 21.5 parts by mass of water. Then, 0.24-0.26 parts by mass of the hydrophilising agent in the form of polioxyethylene-20-sorbitan monostearate and 3.8-4.2 parts by mass of potato starch paste with absorbed quinidine base are added to the resultant pap. The paste contains 2.9-3.1 parts by mass of starch and 0.935-1.075 parts by mass of quinidine base. The cooled-down suspension at room temperature is diluted with 0.5 parts by mass of water. The resultant liquid is instilled on the surface of 150 parts by volume of a desolvating liquid, containing saturated solution of sodium acetate, heptane and liquid paraffin in the volumetric proportion of 1:1:1. The macromolecules are filtered after about 1/2 h and dried at room temperature.
More than twenty two thousand people live with chronic myelogenous leukemia in the United States and more than five thousand people are expected to be diagnosed this year. The majority of patients with this disease are diagnosed in what is called the chronic phase. The standard treatment for this phase of the disease is therapy with a medication called imatinib. This treatment can diminish the amount of disease to very low levels that only very sensitive and specialized techniques can measure; it does not, however, provide a cure.

Dr. Shaoguang Li and colleagues at University of Massachusetts have published a unique discovery that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a critical regulator for LSCs in BCR-ABL-induced CML (Chen Y et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics 41:783-792, 2009). In the absence of Alox5, BCR-ABL failed to induce CML in preclinical studies. While deficiency in Alox5 had no effect on normal hematopoiesis, impairment of the LSCs function through differentiation and cell division of CML LSCs was observed. This defect led to a depletion of LSCs and a failure of CML development. Treatment with a 5-LO inhibitor (zileuton) also impaired the function of LSCs and prolonged survival. These results demonstrate that a specific target gene can be found in cancer stem cells and its inhibition can completely inhibit the function of these stem cells. These findings provide an exciting opportunity to develop the first anti-cancer stem cell therapy for treating CML.
FIRAZYR is supplied as a single-dose, prefilled syringe for subcutaneous administration. Each syringe delivers 3 mL of a sterile solution of icatibant 30 mg (as icatibant acetate). Each glass syringe has a bromobutyl plunger stopper, which is not made of latex natural rubber.

FIRAZYR is available in cartons containing one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 54092-702-02.

FIRAZYR is also available in a pack containing 3 cartons; each carton contains one single-dose, prefilled syringe and one 25 G Luer lock needle. NDC 54092-702-03.
PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
Over 40% of patients with bowel cancer are over the age of 75. In older patients, rates of ill health and frailty are high, with frailty found in 6 in 10 patients over the age of 90. Surgery is the main treatment for bowel cancer, but the risks of surgery are higher in older people especially if they are frail. The main features of frailty are weight loss, lack of energy, weakness, slow walking speed and low activity levels. Frailty is a condition linked to an increased risk of death and major complications after surgery. As a result, older and frailer patients are often refused surgery for their cancer. If we could identify frailty more reliably before surgery, we could offer patients better counselling about the surgical risks and benefits. We could also offer treatments that might improve their fitness, making the surgery safer (pre-operative exercise, better post-operative support). Surgeons are not very good at measuring frailty because the clinical tests for it are complicated and take a long time to complete.
OBJECTIVES: The aim of this study was to assess the efficacy of pelvic osteotomy and ventral fixation of the ischium using cortical screws and polymethylmethacrylate (PMMA) for feline pelvic canal stenosis (PCS) associated with malunion after conservative management of pelvic fractures.
METHODS: Surgical pelvic enlargement was performed for PCS in six cats. The medical records, including information on the patients, surgical procedures, defecation and complications, were reviewed. The sacral index (SI) and colonic:lumbar:vertebral ratio (CLVR) were evaluated based on pre- and postoperative radiographs.
RESULTS: This study included five castrated male cats and one spayed female cat. Postoperative improvements in constipation and defecatory difficulty were noted in all cases. The postoperative SI was significantly higher (mean 0.93, range 0.72-1.13) than the preoperative SI (mean 0.59, range 0.45-0.74) (P <0.001). However, no statistically significant change was found in the CLVR preoperatively and up to 3 months postoperatively. A successful union of the ilium was observed, without implant failures. One case developed necrosis of the pubic surgical wound.
CONCLUSIONS AND RELEVANCE: This study indicated the potential benefits of pelvic osteotomy and ventral fixation of the pelvic floor using screws and PMMA for achieving pelvic cavity enlargement in treating feline PCS associated with defecatory problems.
1390503 Liquid detergent compositions UNILEVER Ltd 29 March 1972 [30 March 1971] 8132/71 Heading C5D An aqueous detergent composition comprises a liquid aqueous medium containing from 1 to 50% by wt. of an organic detergent and at least 1% by wt. of a non-detergent electrolyte and, suspended in the medium, capsules containing core material and having at their surface a water-soluble polymer gel, in which the electrolyte and its concentration in the medium and the polymer gel are such that the polymer gel is insoluble in the medium, but dissolves with release of the core material when the composition is diluted with water. The capsules preferably contain 2 to 30% by wt. of polymer gel, in the form of a wall surrounding the core material. The core material may be liquid, e.g. lemon oil, ethylene glycol and liquid paraffin or solid, e.g. bleach, fluorescers, foam boosters, cosmetics and organic detergents. The polymer gel may be a polysaccharide such as pectin, carrageenan, alginic acid and amylopectin; a cellulose ether, e.g. carboxymethyl cellulose; a protein gelatin; or a synthetic polymer such as polyvinyl alcohol, polyvinyl acetate polyacrylic acid and polyethylene oxide. The electrolyte may be an alkali metal or ammonium salt of citric, tartaric, maleic, oxalic or other organic acid; an alkali metal or ammonium chloride, sulphate, pyrophosphate, tripolyphosphate or dihydrogen ortho phosphate. The capsules may be from 1 micron in diameter up to 500 to 4000 microns. Suspending agents such as synthetic montmorillonite clays and carboxyvinyl polymers may be present. The organic detergent may be an anionic, non- ionic or cationic surfactant. The liquids are of general application, e.g. dish-washing compositions, shampoos, bath preparations and heavy duty liquids for washing textiles. Specifications 1,262,280, 1,303,810 and 1,308,190 are referred to.
Oxidative stress and endoplasmic reticulum stress (ERS) was associated with the development of asthma. Edaravone (EDA) plays a classical role to prevent the occurrence and development of oxidative stress-related diseases. Herein, we investigated the involvement and signaling pathway of EDA in asthma, with particular emphasis on its impact on type 2 innate lymphoid cells (ILC2) and CD4+T cells, and then further elucidated whether EDA could inhibit house dust mite (HDM)-induced allergic asthma by affecting oxidative stress and ERS. Mice received intraperitoneally injection of EDA (10 mg/kg, 30 mg/kg), dexamethasone (DEX) and N-acetylcysteine (NAC), with the latter two used as positive control drugs. DEX and high dose of EDA showed better therapeutic effects in alleviating airway inflammation and mucus secretion in mice, along with decreasing eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) than NAC. Further, the protein levels of IL-33 in lung tissues were inhibited by EDA, leading to reduced activation of ILC2s in the lung. EDA treatment alleviated the activation of CD4+ T cells in lung tissues of HDM-induced asthmatic mice and reduced Th2 cytokine secretion in BALF. ERS-related markers (p-eIF2α, IRE1α, CHOP, GRP78) were decreased after treatment of EDA compared to HDM group. Malondialdehyde (MDA), glutathione (GSH), hydrogen peroxide (H2O2), and superoxide dismutase (SOD) were detected to evaluate the oxidant stress in lung tissues. EDA showed a protective effect against oxidant stress. In conclusion, our findings demonstrated that EDA could suppress allergic airway inflammation by inhibiting oxidative stress and ERS, suggesting to serve as an adjunct medication for asthma in the future.
PURPOSE: To develop an effect of increasing the weights of livestock, etc., by compounding forskolin or its similar compds. with solid or liquid complete feed, auxiliary feed, potable water, etc., thereby preparing the growth accelerator of the livestock. CONSTITUTION: At least one kind of the forskolin or its similar compds. are compounded with the solid or liquid complete feed, the auxiliary feed, the potable water, etc., by which the medicine to accelerate the weight increase of the livestock having single or many stomachs and improved feed conversion or both thereof is prepd. The shapes of the medicine include solid and liquid pharmaceuticals for oral dosage, tablets, capsules, paste, granules, powders, solns., syrups, etc. The amt. of the forskolin or its similar compds. to be compounded is adequately 0.1 to 500mg, more adequately 0.1 to 200mg and more particularly adequately 0.1 to 100mg per 1kg feed.
TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
This study is a single-center, prospective, two-arm study to evaluate the efficacy and safety of alveolar bone regeneration induced by gelatin sponge-loaded apoptotic vesicle complex in patients with mandibular third molar extraction. This study plans to include 30 subjects from the Department of Stomatology of the Fifth Affiliated Hospital of Guangzhou Medical University. One socket for each participant in this study will receive gelatin sponge-loaded apoptotic vesicle complex after third molar extraction and socket debridement. The other side of socket for each participant in this study will receive commercial gelatin sponge after the same surgery. All participants will undergo screening and baseline visits. After surgery, the participants will be followed up for 1 year.
An internal medicine for gastro-intestinal diseases comprises a balsam dispersed in one or more bland fatty substances by heating and/or mechanical means to a balsam particle size of approximately 5 to 10 microns.  Balsam of Peru is preferred, although Balsam of Copaiba, Balsam of Tolu and Canada Balsam may be used.  The bland fatty substances are vegetable and animal fats and oils having no purgative or cathartic effect and comprise mutton tallow, lard, butter and lanolin, which is preferred. Mixtures of these may also be used.  Chlorophyll preferably in solution in oil, choline, esters thereof especially carbachol and amino acids, e.g., in the form of plasmolyzed yeast may also be added.  Plasmolyzed yeast extract consists of arginine, histidine, lysine, tyrosine, tryptophane, phenylalanine, cystine, methionine, threonine, leucine, isoleucine and valine.  In one method of preparation the materials are mixed, heated just sufficiently to melt the mixture and passed through a colloid mill.  In another, the balsam and lanoline is heated on a water bath at 212 DEG F with stirring until the dispersed resin is of the aforesaid micron size and the insoluble resin which settles to the bottom of the bath is separated therefrom.
American football is one of the most popular sports in the U.S. Yet this sport is associated with increased risk of concussion (also known as mild traumatic brain injury, or mTBI) and sub-concussive injury from repeated head impacts (RHI) due to the aggressive and high-speed nature of the game. Current protective equipment used by players are not sufficient to reduce concussion incidence and severity, nor are there any therapeutics available to prevent concussion. This study is a randomized, double-blind, placebo controlled trial to determine if an omega-3 polyunsaturated fatty acid (PUFA) fish oil supplement containing 3.0 grams of docosahexaenoic acid (DHA; 22:6n-3) and eicosapentaenoic acid (EPA; 20:5n-3) can reduce blood biomarkers of sub-concussion injuries compared to placebo (high-oleic safflower oil) over a course of the American football season among collegiate football athletes.

The dosage of DHA/EPA used in this study is generally safe, and procedures involved, monthly blood draws, surveys, and Magnetic Resonance Imaging (MRI), pose minimal risks to participants. While this study provides no direct benefit to participants, successful outcomes of this study can benefit the society by shedding light on development of potential preventative therapeutics for sports-induced mTBI and brain injury from RHI. The risk-benefit profile is appropriate for conducting this study. Based on preclinical studies and previous clinical study results, the investigators expect that in comparison to placebo treatment, DHA and EPA treatment throughout the course of one American football season can maintain lower levels of sub-concussion associated biomarkers, inflammatory cytokines, and cardiovascular risk markers. The investigators also expect participants treated with DHA and EPA to have lower brain MRI imaging markers of sub concussion injury.
The invention relates to a traditional Chinese medicine composition for preventing and treating poultry coccidiosis and a preparation method of the traditional Chinese medicine composition. The medicine materials of the traditional Chinese medicine composition comprise antifebrile dichroa, radix sophorae flavescentis, flos chrysanthemi indici, garlic, cogongrass rhizome, carbonized sanguisorba root, hairyvein agrimony, golden cypress, dandelion, rhizoma atractylodis, fennel, astragalus mongholicus, coptis chinensis and radix bupleuri. By using the traditional Chinese medicine composition, the purpose of preventing and treating coccidiosis in chicken can be effectively achieved in the aspects of expelling parasite, preventing malaria, hemostasis, cooling blood, clearing heat, diminishing inflammation and nourishing. In addition, two technologies of extraction and superfine grinding are adopted in a manufacturing process so that the utilization rate and biological solubility of the traditional Chinese medicines are significantly improved. Water or mixed materials can be taken during administration so that the clinical application is more convenient. Furthermore, the traditional Chinese medicine composition is prepared from pure traditional Chinese medicines, has no drug residue and has no toxic and side effects on an organism.
Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
One in seven men will be diagnosed with cancer of the prostate during his lifetime . Accordingly, prostate cancer (PC) is the most common cancer amongst men in the western world and worldwide. PC ranks second in cancer incidence and sixth in cancer mortality in men. The current standard of care for patients with metastatic castration resistant prostate cancer (mCRPC) and disease progression is either treatment with abiraterone acetate and prednisone in asymptomatic or mildly symptomatic patients without visceral metastases, or treatment with docetaxel in more symptomatic patients and in the presence of visceral metastases.

Rothemundt et al. previously demonstrated favorable effects of metformin in a phase II trial: it yields objective Prostate specific antigen PSA responses and may induce disease stabilization and improve metabolic endpoints in patients with CRPC. Therefore addition of metformin to enzalutamide might have positive impact on tumor progression, on body composition, and insulin sensitivity.
Adult patients definitive post-thyroidectomy HoPT defined by a parathyroid hormone (PTH) concentration ≤ 25 pg/mL more than 6 months after the operation and who require treatment with vitamin D and/or calcium supplementation. Each patient will complete a questionnaire twice (3 weeks apart +/- 7 days). The questionnaire, which evaluates the severity of clinical symptoms related to HoPT and their impact on quality of life, is adapted to this pathology.